Financial Metrics Check: Lexicon Pharmaceuticals Inc (LXRX)’s Ratios for Trailing Twelve Months

The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In other words, the price has increased by $0.00 from its previous closing price. On the day, 1.81 million shares were traded. LXRX stock price reached its highest trading level at $1.8 during the session, while it also had its lowest trading level at $1.73.

Ratios:

To gain a deeper understanding of LXRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.49 and its Current Ratio is at 11.51. In the meantime, Its Debt-to-Equity ratio is 0.44 whereas as Long-Term Debt/Eq ratio is at 0.43.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 17, 2024, initiated with a Buy rating and assigned the stock a target price of $10.

On April 30, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $5.

On March 07, 2023, Jefferies started tracking the stock assigning a Hold rating and target price of $3.Jefferies initiated its Hold rating on March 07, 2023, with a $3 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 15 ’24 when COATS LONNEL bought 300,000 shares for $1.60 per share.

COATS LONNEL bought 90,000 shares of LXRX for $94,797 on Nov 16 ’23. The Chief Executive Officer now owns 914,359 shares after completing the transaction at $1.05 per share. On Nov 10 ’23, another insider, COATS LONNEL, who serves as the Chief Executive Officer of the company, bought 10,000 shares for $1.01 each. As a result, the insider paid 10,100 and bolstered with 824,359 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 647070656 and an Enterprise Value of 442783200. For the stock, the TTM Price-to-Sale (P/S) ratio is 177.77 while its Price-to-Book (P/B) ratio in mrq is 2.70. Its current Enterprise Value per Revenue stands at 121.61 whereas that against EBITDA is -2.254.

Stock Price History:

Over the past 52 weeks, LXRX has reached a high of $3.73, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is 7.33%, while the 200-Day Moving Average is calculated to be -5.30%.

Shares Statistics:

It appears that LXRX traded 2.79M shares on average per day over the past three months and 2111810 shares per day over the past ten days. A total of 361.49M shares are outstanding, with a floating share count of 349.07M. Insiders hold about 3.44% of the company’s shares, while institutions hold 76.87% stake in the company. Shares short for LXRX as of 1727654400 were 26971057 with a Short Ratio of 9.67, compared to 1724976000 on 25393364. Therefore, it implies a Short% of Shares Outstanding of 26971057 and a Short% of Float of 16.549999.

Most Popular